2022-10-18| M&A

Eli Lilly Snatches Up Akouos Treating Ear Conditions for $487 million

by Max Heirich
Share To

Eli Lilly announced a definitive agreement for their acquisition of a precision genetic medicine company, Akouos, on October 18. The relatively young company is known for its portfolio containing a slew of gene therapies treating inner ear conditions.

The value of the proposed deal is around $487 million. However, certain milestones could result in a bump in the total payment. This marks Eli Lilly’s second gene therapy acquisition after they picked up Prevail Therapeutics in 2021. 

Related Article: Novo Nordisk Finally Finalizes their Billion Dollar Acquisition of Forma Therapeutics

Treating Ear Conditions With Gene Therapy

Akouos started in 2016 with a focus on providing gene therapies for hearing loss, specifically centered on conditions in the inner ear. Among their developing pipeline are treatments such as AK-OTOF. 

AK-OTOF is a dual adeno-associated viral (AAV) vector-based gene therapy designed for treating OTOF-mediated hearing loss, a condition resulting from mutations in the otoferlin gene. This gene encodes the protein otoferlin, resulting in inner hair cells of the cochlea releasing neurotransmitter vesicles as a response to sound stimulation from auditory neurons. 

In September this year, the United States Food and Drug Administration (FDA) granted clearance for AK-OTOF’s advancement into a pediatric Phase 1/2 clinical trial. Currently, there are no other gene therapies available for the treatment of this sort of hearing loss. 

Considered their flagship product, AK-OTOF only makes up one part of Akouos’ developing pipeline, which caught Eli Lilly’s attention.

Millions Funneled into Treating Ear Conditions

The terms of the agreement between Eli Lilly and Akouos lists price per share at around $12.50 per share in cash for an approximate total of $487 million. However, contingent value right holders are entitled to additional payments for up to $15 per share or $610 million in total. Eli Lilly’s only other gene therapy acquisition occurred in 2021, where they grabbed Prevail Therapeutics for a total of $1.04 billion.

This extra money is contingent on a number of factors, including the administration of the fifth patient with the AK-OTOF gene therapy before December 31, 2024. Other factors include other milestones centered around the administration of various treatments.

On the acquisition, Emmanuel Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, said, “Joining Lilly – a company that shares our purpose to make life better for people around the world – will help us accelerate the development of a broad pipeline of inner ear genetic medicines.”

Both companies’ boards of directors approved the acquisition, with a target closing date sometime in the fourth quarter of 2022. A second-step merger will acquire any non-tender shares remaining after the successful closing. 

© All rights reserved. Collaborate with us:
Related Post
EMA Plans to Issue Liver Failure Warning for Novartis’ Gene Therapy
Will Breakthrough Therapy Lead the Way? An Overview of the Approved Gene and Cell Therapies for 2022
JPM23: More Deals as JP Morgan Healthcare Conference 2023 Enters the Third Day
NDA for Biogen-Sage’s Zuranolone Accepted by FDA, Marking Another Step Forward in Depression Drug Development
BMS Returns $475 Million Cancer Asset To Dragonfly Therapeutics
FDA Expands Approval For Takeda’s Takhzyro To Prevent Hereditary Angioedema Attacks
Abbott’s New Technologies for Arrhythmia Treatment Secure FDA and European Approval
First Human Trial for Marburg Virus Vaccine Reports Success
Karuna Licenses Goldfinch’s Mood Disorder Candidates For Potential $535 Million
Novel Bioengineered Wearable Edgeless Skin Brings Hope to Revolutionize Plastic and Reconstructive Surgery
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!